KALA BIO, Inc S-3, filed Mar 3, 2023
KALA BIO, Inc. (KALA)
SECURITIES AND EXCHANGE COMMISSION
REGISTRATION STATEMENT
THE SECURITIES ACT OF 1933
| |
Delaware
|
| |
27-0604595
|
|
| |
(State or other jurisdiction of
incorporation or organization) |
| |
(I.R.S. Employer
Identification Number) |
|
Arlington, MA 02476
(781) 996-5252
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Chief Executive Officer
Kala Pharmaceuticals, Inc.
1167 Massachusetts Avenue
Arlington, MA 02476
(781) 996-5252
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)
| |
Stuart M. Falber
Scott N. Lunin Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, MA 02109 Telephone: (617) 526-6000 |
| |
Eric L. Trachtenberg
General Counsel, Chief Compliance Officer and Corporate Secretary Kala Pharmaceuticals, Inc. 1167 Massachusetts Avenue Arlington, MA 02476 Telephone: (781) 996-5252 |
|
| | Large accelerated filer | | | ☐ | | | Accelerated filer | | | ☐ | |
| | Non-accelerated filer | | | ☒ | | | Smaller reporting company | | | ☒ | |
| | | | | | | | Emerging growth company | | | ☐ | |
| | | |
Page
|
| |||
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 11 | | | |
| | | | | 15 | | | |
| | | | | 17 | | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| |
Common Stock Offered by Selling Stockholders
|
| | 5,391,213 shares, consisting of 76,813 outstanding shares of our common stock and 5,314,400 shares of our common stock issuable upon the conversion of outstanding shares of Series E Preferred Stock. | |
| |
Use of Proceeds
|
| | We will not receive any proceeds from the sale of shares in this offering. | |
| |
Risk Factors
|
| | You should read the “Risk Factors” section of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. | |
| |
Nasdaq Capital Market Symbol
|
| | “KALA” | |
| | | |
Shares of
Common Stock Beneficially Owned Prior to Offering |
| |
Number of
Shares of Common Stock Being Offered(1) |
| |
Shares of
Common Stock to be Beneficially Owned After Offering(2) |
| | | | | | | |||||||||||||||||||||
|
Name of Selling Stockholder
|
| |
Number
|
| |
Percentage
|
| |
Number
|
| |
Percentage
|
| | | | | ||||||||||||||||||||
|
Entities affiliated with Baker Bros. Advisors LP(3)
|
| | | | 218,427 | | | | | | 9.99% | | | | | | 5,391,213 | | | | | | — | | | | | | —% | | | | | ||||
1167 Massachusetts Avenue
Arlington, MA 02476
Attn: Investor Relations
(781) 996-5252
| |
SEC registration fee
|
| | | $ | 6,381 | | |
| |
Legal fees and expenses
|
| | | $ | 40,000 | | |
| |
Accounting fees and expenses
|
| | | $ | 20,000 | | |
| |
Printing fees and expenses
|
| | | $ | 3,000 | | |
| |
Miscellaneous fees and expenses
|
| | | $ | 5,619 | | |
| |
Total expenses
|
| | | $ | 75,000 | | |
|
Exhibit No.
|
| |
Description
|
|
|
4.4
|
| | Registration Rights Agreement, dated March 2, 2023, by and among the Registrant and the other parties thereto (incorporated by reference to Exhibit 4.5 to the Registrant’s annual report on Form 10-K (File No. 001-38150) filed on March 3, 2023). | |
|
5.1
|
| | | |
|
23.1
|
| | | |
|
23.2
|
| | | |
|
24.1
|
| | | |
|
107
|
| | |
| |
Signature
|
| |
Title
|
| |
Date
|
|
| |
/s/ MARK IWICKI
Mark Iwicki
|
| |
Chief Executive Officer and
Chairman of Board of Directors (Principal Executive Officer) |
| |
March 3, 2023
|
|
| |
/s/ MARY REUMUTH
Mary Reumuth
|
| |
Chief Financial Officer
(Principal Financial and Accounting Officer) |
| |
March 3, 2023
|
|
| |
/s/ MARK S. BLUMENKRANZ
Mark S. Blumenkranz, M.D.
|
| |
Director
|
| |
March 3, 2023
|
|
| |
/s/ MARJAN FARID
Marjan Farid, M.D.
|
| |
Director
|
| |
March 3, 2023
|
|
| |
/s/ ANDREW I. KOVEN
Andrew I. Koven
|
| |
Director
|
| |
March 3, 2023
|
|
| |
/s/ C. DANIEL MYERS
C. Daniel Myers
|
| |
Director
|
| |
March 3, 2023
|
|
| |
/s/ ROBERT PAULL
Robert Paull
|
| |
Director
|
| |
March 3, 2023
|
|
| |
/s/ GREGORY PERRY
Gregory Perry
|
| |
Director
|
| |
March 3, 2023
|
|
| |
/s/ HOWARD B. ROSEN
Howard B. Rosen
|
| |
Director
|
| |
March 3, 2023
|
|
Exhibit 5.1

+1 617 526 6000 (t)
+1 617 526 5000 (f)
wilmerhale.com
March 3, 2023
Kala Pharmaceuticals, Inc.
1167 Massachusetts Avenue
Arlington, MA 02476
Re: Registration Statement on Form S-3
Ladies and Gentlemen:
This opinion is furnished to you in connection with a Registration Statement on Form S-3 (the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities Act”), for the registration of the resale of an aggregate of 5,391,213 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of Kala Pharmaceuticals, Inc., a Delaware corporation (the “Company”). All of the Shares are being registered on behalf of certain stockholders of the Company (the “Selling Stockholders”). The Shares consist of (i) 76,813 outstanding shares of Common Stock (the “Outstanding Shares”) that are held by the Selling Stockholders and (ii) 5,314,400 shares of Common Stock issuable upon the conversion of shares of Series E Convertible Non-Redeemable Preferred Stock, par value $0.001 per share (the “Series E Preferred Stock” and such shares, the “Conversion Shares”), that are held by the Selling Stockholders.
We are acting as counsel for the Company in connection with the registration for resale of the Shares. We have examined signed copies of the Registration Statement as filed with the Commission. We have also examined and relied upon minutes of meetings of the stockholders and the Board of Directors of the Company as provided to us by the Company, the stock record books of the Company as provided to us by the Company, the Restated Certificate of Incorporation of the Company, including Certificate of Designation of the Series D Preferred Stock of the Company, Certificate of Elimination of Number of Shares of Preferred Stock Designated as Series D Preferred Stock of the Company and Certificate of Designations, Preferences and Rights of Series E Convertible Non-Redeemable Preferred Stock of the Company (as restated and/or amended to date, the “Certificate of Incorporation”) and the Amended and Restated By-Laws of the Company (as restated and/or amended to date, the “By-Laws”), and such other documents as we have deemed necessary for purposes of rendering the opinions hereinafter set forth.
In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents.
Our opinion below, insofar as it relates to the Selling Stockholders’ shares being fully paid, is based solely on a certificate of the Chief Financial Officer of the Company confirming the Company’s receipt of the consideration called for by the applicable resolutions authorizing the issuance of such shares.
We assume that the appropriate action will be taken, prior to the offer and sale of the Shares by the Selling Stockholders, to register and qualify the Shares for sale under all applicable state securities or “blue sky” laws.
We express no opinion herein as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware.
Based upon and subject to the foregoing, we are of the opinion that (i) the Outstanding Shares have been duly authorized and are validly issued, fully paid and nonassessable, and (ii) the Conversion Shares have been duly authorized for issuance and, when issued and delivered upon conversion of the Series E Preferred Stock in accordance with the terms of the Company’s Certificate of Incorporation, will be validly issued, fully paid and nonassessable.

Kala Pharmaceuticals, Inc.
March 3, 2023
Page 2

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.
Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.
We hereby consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of our name therein and in the related prospectus under the caption “Legal Matters.” In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.
| Very truly yours, | |
| /s/ Wilmer Cutler Pickering Hale and Dorr LLP | |
| WILMER CUTLER PICKERING HALE AND DORR LLP |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated March 3, 2023 relating to the financial statements of Kala Pharmaceuticals, Inc. and its subsidiaries, appearing in the Annual Report on Form 10-K of Kala Pharmaceuticals, Inc. for the year ended December 31, 2022. We also consent to the reference to us under the heading "Experts" in such Registration Statement.
| /s/ Deloitte & Touche LLP | |
| Boston, Massachusetts | |
| March 3, 2023 |